1,1,2,2-TETRA (HETERO) ARYLETHANES OR 1,1,2-TRI (HETERO) ARYL-2-HETEROCYCLYLETHANES AS POTASSIUM CHANNEL INHIBITORS

FIELD: chemistry. ^ SUBSTANCE: this invention refers to compounds chosen from group including (R)-N-{6-[1-(4-fluorophenyl)-2,2-dipyridine-3-ylethyl]pyridine-2-yl}methane sulphonamide, (S)-N -{6-[1-(4- fluorophenyl])-2,2-dipyridine-3-ylethyl] pyridine-2-yl}methane sulphonamide, (R)-N-{6-[1-(3-cyanophenyl)-2,2-dipyridine-3-ylethyl]pyridine-2-yl}methane sulphonamide, (S)-N-{6-[1-(3-cyanophenyl)-2,2-dipyridine-3-ylethyl]pyridine-2-yl}methane sulphonamide, (R)-N-{6-[1-(6-methoxypyridine-6-yl)-2,2-dipyridine-3-ylethyl]pyridine-2-yl}methane sulphonamide, (S)-N-6-[1-(6-methoxypyridine-6-yl)-2,2-dipyridine-3-ylethyl]pyridine-2-yl}methane sulphonamide, (R)-3-[1-(2-aminopyrimidine-2-yl)-2,2-dipyridine-3-ylethyl]benzonitrile and (S)-3-[1-(2-aminopyrimidine-2-yl)-2,2-dipyridine-3-ylethyl]benzonitrile, as well as to method of mammal treatment performed or facilitated with Kv1.5 inhibition, to pharmaceutical preparation with Kv1.5 inhibiting action and to pharmaceutical composition with Kv1.5 inhibiting action. ^ EFFECT: production of new compounds which can be applied as potassium channel inhibitors for heart arrhythmia treatment. ^ 6 cl, 5 ex